Zacks Investment Research
01 Oct 2026, 18:31 UTC · 22h ago
Verdict
Headline leans bearish. We score LQDA −1.00 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
The U.S. District Court for the District of Delaware ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia.
Newpublished October 01, 2026
More negative than 99% of claims this week
Liquidia's share price declined 57% following the court ruling.
New
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 91% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company suffered a major setback with a court ruling of patent infringement, leading to a 57% share price decline.
More positive than 99% of ticker scores this week
The court ruled that two of the company's patent claims are valid and were infringed by a competitor.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
13h ago
−9.6%
Price agrees with the score
$27.34 vs $30.26 close before publication (Sep 30) · not market-adjusted
LQDA chart →
